OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker Consortium
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • 2024 nominations are open for Giants of Cancer Care®
  • In-person and virtual events just for HCPs
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
Advertisement

Post-Conference Perspectives: Update on PARP Inhibitors in Breast Cancer

home / news-network / sabcs-2018-parp-inhibitors
Advertisement
A PARP/I-O Strategy in Breast Cancer: The MEDIOLA Trial

EP. 1: A PARP/I-O Strategy in Breast Cancer: The MEDIOLA Trial

December 28th 2018
PARP Inhibition as Neoadjuvant Therapy in Breast Cancer

EP. 2: PARP Inhibition as Neoadjuvant Therapy in Breast Cancer

December 28th 2018
Adding Olaparib to Chemotherapy in TNBC: The PARTNER Trial

EP. 3: Adding Olaparib to Chemotherapy in TNBC: The PARTNER Trial

December 28th 2018
PARP/Checkpoint Inhibition in TNBC: The TOPACIO Trial

EP. 4: PARP/Checkpoint Inhibition in TNBC: The TOPACIO Trial

December 28th 2018
Future Roles of PARP Inhibition in Breast Cancer

EP. 5: Future Roles of PARP Inhibition in Breast Cancer

December 28th 2018

Latest Conference Coverage

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

Dr Habib on Developments in Palliative Care For Patients With Cancer

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact